For instance, immunotherapies combining targeting CD47/signal-regulatory protein alpha (SIRPα), an innate anti-phagocytic axis between tumor cells and macrophages were shown to elicit synergistic anti-cancer activities in both hematologic malignancies and solid tumors [[132], [133], [134]]. The gene discussed is SIRPA; the disease is hematologic disorder.